Blood Journal
Leading the way in experimental and clinical research in hematology

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

  1. Cindy Neunert1,*,
  2. Wendy Lim2,*,
  3. Mark Crowther3,
  4. Alan Cohen4,
  5. Lawrence Solberg Jr5, and
  6. Mark A. Crowther2
  1. 1University of Texas, Southwestern Medical Center, Dallas, TX;
  2. 2McMaster University, Hamilton, ON;
  3. 3Worcestershire Royal Hospital, Worcester, United Kingdom;
  4. 4Children's Hospital of Philadelphia, Philadelphia, PA; and
  5. 5Mayo Clinic, Jacksonville, FL


Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been numerous advances in the management of both adult and pediatric ITP. These changes mandated an update in the guidelines. This guideline uses a rigorous, evidence-based approach to the location, interpretation, and presentation of the available evidence. We have endeavored to identify, abstract, and present all available methodologically rigorous data informing the treatment of ITP. We provide evidence-based treatment recommendations using the GRADE system in those areas in which such evidence exists. We do not provide evidence in those areas in which evidence is lacking, or is of lower quality—interested readers are referred to a number of recent, consensus-based recommendations for expert opinion in these clinical areas. Our review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of “front-line” therapy for ITP, the management of serious bleeding in patients with ITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention.

  • Submitted August 20, 2010.
  • Accepted January 18, 2011.
View Full Text